The Vbeam 595 nm Pulsed Dye Laser, a Recognized Gold Standard for Vascular Treatment, Receives a Ground-Breaking FDA Clearance for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Population – the First Clearance of its Kind.

Candela Corporation (Candela), a leading global medical aesthetic device company headquartered in Marlborough, MA, today announced that the Vbeam Family of Pulsed Dye Lasers (PDL) has expanded its FDA cleared indications for use of the 595 nm wavelength to include the pediatric population (from birth – 21 years of age) for treatment of cutaneous capillary malformations, also known as port wine stains (PWS), and infantile hemangiomas (IH) / congenital hemangiomas.*

Read the full press release featuring our own Dr. Geronemus on PR Newswire and the Dermatology Times.